Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.36 |
| ▸ | TUBB | P07437 | 3/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.36 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.36 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.36 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.36 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15010425 | 0.92 | EGFR (0.47) | EGFRHTR2AHTR2CHTR2BENPP2 | |
| SCHEMBL2411894 | 0.85 | NPC1 (0.42) | EGFRHTR2AHTR2CHTR2BENPP2 | |
| SCHEMBL1756413 | 0.84 | ENPP2 (0.45) | EGFRHTR2AHTR2CHTR2BENPP2 | |
| SCHEMBL15010189 | 0.84 | ENPP2 (0.45) | EGFRHTR2AHTR2CHTR2BENPP2 | |
| SCHEMBL29954382 | 0.84 | ENPP2 (0.45) | EGFRHTR2AHTR2CHTR2BENPP2 | |
| SCHEMBL29954676 | 0.84 | ENPP2 (0.45) | EGFRHTR2AHTR2CHTR2BENPP2 | |
| SCHEMBL28041850 | 0.82 | GAA (0.52) | EGFRENPP2TUBB4ATUBBTUBA3C | |
| SCHEMBL29951081 | 0.78 | ENPP2 (0.41) | EGFRENPP2TUBB4ATUBBTUBA3C | |
| SCHEMBL15010879 | 0.78 | ENPP2 (0.41) | EGFRENPP2TUBB4ATUBBTUBA3C | |
| SCHEMBL19756672 | 0.77 | HTR2A (0.47) | EGFRHTR2AHTR2CHTR2BTUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20130303537-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUNDS HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-1995242-B1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-1995242-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995242-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | EGFR 3869/4885HTR2A 2891/4885HTR2C 3873/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | EGFR 3869/4885HTR2A 2891/4885HTR2C 3873/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | EGFR 3869/4885HTR2A 2891/4885HTR2C 3873/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | EGFR 3486/4885HTR2A 3505/4885HTR2C 3383/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | EGFR 1147/4885HTR2A 895/4885HTR2C 1336/4885 |
| US-20130303537-A1 | 1,2,3,4-TETRAHYDROQUINOXALINE COMPOUNDS HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | NR3C1, NR3C2, NR5A1 | EGFR 2719/4885HTR2A 617/4885HTR2C 505/4885 |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | NR3C1, NR3C2, MC2R | EGFR 3355/4885HTR2A 568/4885HTR2C 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.